Navigation Links
Palette Life Sciences Announces the Solesta Reimbursement Assistance Program
Date:2/10/2020

Palette Life Sciences, Inc., a medical device company dedicated to assisting healthcare professionals (HCPs) to improve patient outcomes in colorectal urologic and oncologic conditions and diseases, today announced the launch of the Solesta® Reimbursement Assistance Program.

Solesta is a minimally-invasive, and easily injectable viscous gel made from two polysaccharides, Non-Animal Stabilized Hyaluronic Acid (NASHA®) and Dextranomer (Dx) microspheres.1 Solesta is the only quick, nonsurgical treatment for fecal incontinence, administered in an outpatient setting without the need for anesthesia.2 HCPs can simply follow three steps at MySolesta.com to become trained in Solesta administration and technique. Studies have shown that Solesta can help patients return to a more active lifestyle (socializing, going to work, etc.) and reduces the depression and embarrassment that is often associated with bowel control problems.3

The new Solesta Reimbursement Assistance Program provides an easy and seamless reimbursement experience for physicians prescribing Solesta for their patients. The program minimizes barriers that can delay or prevent access to Solesta by providing personalized reimbursement support to physicians and their patients. Physicians simply complete the Service Request Form located on MySolesta.com and submit it to the Solesta Reimbursement Assistance Program. This one-step program for physicians and their staff assumes no financial risk for product acquisition. Once approved, Solesta will be shipped directly to the physician’s office.

“In past years, it was nearly impossible for physicians and patients to receive reimbursement for Solesta. We physicians had to endure financial risk in ordering Solesta for our patients and patients often found the product unaffordable, at times,” said Dr. Zuri Murrell, Los Angeles based colorectal surgeon and specialist. “The new Solesta Reimbursement Assistance Program mitigates the reimbursement problem. My office staff was pleasantly surprised with the simplicity and effectiveness of the new reimbursement program. In the short amount of time that the program has existed, many patients have received the Solesta treatment at a reasonable cost.”

"Seeking reimbursement for any product can be a time-consuming process for you and your office staff. When it comes to product reimbursement for Solesta, we’re here to help," said Richard Low, Head of Marketing, Palette Life Sciences. “The program is designed to help offices save time and energy while keeping physicians and their staff informed every step of the way.”

Other resources available at MySolesta.com include more detailed clinical and procedure training information for physicians, as well as education materials for patients in both written and video formats, so that they know what to expect with the Solesta treatment. The site also includes a Physician Locator for patients.

For more information on the Solesta Reimbursement Assistance Program, call 1-877-546-7150; email info@palettelifesciences.com or visit MySolesta.com.

About Solesta

Solesta®, a Non-Animal Stabilized Hyaluronic Acid (NASHA®) and dextranomer gel, is a tissue bulking agent that is injected into the submucosal layer of the anal canal for treatment of Fecal Incontinence in adults. It’s a minimally invasive, outpatient procedure that improves Quality of Life and has been proven effective for up to 36 months.1 Learn more at MySolesta.com.

About Palette Life Sciences

Palette Life Sciences is focused on providing a wide range of products and services that improve quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Palette Life Sciences, Inc. is a wholly owned subsidiary of Pharmanest AB headquartered in Stockholm, Sweden. Learn more at MySolesta.com and palettelifesciences.com.    

References

1.    Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children. Adv Urol. 2008;513854.

2.    Solesta [Package Insert]. Santa Barbara, CA: Palette Life Sciences.

3.    Graf W, Mellgren KE, et al; for NASHA Dx study group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, shame-controlled trial. Lancet. 2011;377(9770):977-1003.

Solesta® and NASHA® are registered trademarks. All rights reserved.

Important Safety Information: http://www.mysolesta.com/important-safety-information

APM088A

Read the full story at https://www.prweb.com/releases/palette_life_sciences_announces_the_solesta_reimbursement_assistance_program/prweb16897257.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related medicine news :

1. The Lash Palette Preorder Event Has Officially Begun
2. Pixel Film Studios Released the ProPalette Spotlight Plugin for Final Cut Pro X Today
3. BTV-Business Television Rising Stars in Life Sciences with Verisante, Vivione, biOasis, Theralase and Aurora Spine
4. Polish Academy Of Sciences awards LSUHSCs Bazan Medal
5. Global Life Sciences Consulting Firm, MAETRICS, Appoints Fortune 100 Sales Executive, R.J. Lemieux.
6. Western University of Health Sciences’ Gala Fundraiser Emphasizes Humanism and Caring
7. NSU's Graduate School of Computer and Information Sciences to Host 2nd Annual ITPalooza
8. £23m to drive advances in population health sciences research
9. NSU’s Graduate School of Computer and Information Sciences to Offer Master of Science in Management Information Systems at Regional Campuses
10. Neuro-Oncology Pioneer Who Defined Standard of Care for Brain and Spinal Tumors Joins Capital Institute for Neurosciences
11. C8 Sciences’ Activate Brain Training Program Receives Blue Ribbon Designation From IBCCES
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/19/2020)... ... February 19, 2020 , ... MedTech IGNITE Expands Steering ... to Participate in 2020 Cohort , The Massachusetts Medical Device Industry Council ( ... accepting applications from startup founders and CEOs to participate in the 2020 IGNITE ...
(Date:2/19/2020)... ... February 19, 2020 , ... ... healthcare delivery, announced that it will participate in the HIMSS20 Global ... Health will engage healthcare professionals and other stakeholders at HIMSS20 – the largest ...
(Date:2/19/2020)... ... February 19, 2020 , ... SEAL SHIELD, LLC - ... result of healthcare-acquired infections (HAIs.) According to The Centers for Disease Control (CDC), 80% ... large amount of screens that are now acting as an extension of people’s hands, ...
(Date:2/16/2020)... ... February 16, 2020 , ... Accumen Inc., ... partnering with AABB and The Joint Commission to provide a complimentary series of ... (directors, managers, coordinators and transfusion safety officers) within U.S. hospitals. , ...
(Date:2/15/2020)... (PRWEB) , ... February 14, 2020 , ... ... cleaning products, partnered with Baptist Easley Hospital , a member of Prisma ... patient environments. With PCPLUS, the world-class hospital was able to cut its monthly ...
Breaking Medicine News(10 mins):
(Date:2/13/2020)... SAN MATEO, Calif. (PRWEB) , ... February 13, 2020 , ... ... about their finances show that they are maintaining a generally positive outlook on ... worrisome contradictory indicators. , Asked if they are better off today than a year ...
(Date:2/11/2020)... Calif. (PRWEB) , ... February 11, 2020 , ... ... in first aid and other safety measures, is offering courses for hospital and ... training is a requirement for medical practitioners like nurses, doctors, and other staff ...
(Date:2/11/2020)... JOLLA, Calif. (PRWEB) , ... February 11, 2020 , ... ... Laser Vision & Eye Center run by Dr. Daniel Coden, Dr. Arthur Perry, and ... Pratt, and Coden have served patients in the La Jolla and San Diego community ...
Breaking Medicine Technology: